Next™ Immunocytokine Engineering Development Service

The Prospect of Cytokine-based Therapeutics

In the tumor microenvironment, cytokines serve as an important mediator of cell communication. A variety of cytokines are involved in the host antitumor response, but in the process of malignant tumor progression, the production and function of these cytokines are often dysregulated. In view of their clinical potential and early successful application in cancer immunotherapy, cytokine-based therapeutics have been widely evaluated in several subsequent clinical trials. Recently, more cytokine engineering strategies aimed at improving the therapeutic effectiveness have been focused by industry and academia.

Fig.1 Different cytokine-based engineering approaches in therapeutics. (Fu, et al., 2023)

Our Next™ Immunocytokine Engineering Development Service

With our superior technology platform, Creative Biolabs specializes in providing customized immunocytokine engineering development services for global customers. As cytokine therapy has a crucial safety concern, it can induce systemic immune activation through diverse receptor expression profiles, causing on-target activity as well as off-tumor activity. Fusing cytokines with targeting or functional proteins, which could modulate their localization or/and add new functions. Based on this feature, we set up relevant platforms to fuse cytokines with antibodies or other targeted candidates, optimize different structural forms to perform immunocytokine engineering, and thus target effector molecules in the tumor microenvironment, enhancing the therapeutic efficacy. Creative Biolabs provides one-stop immunocytokine engineering development services to meet global customers' needs.

Fig.2 Various formats of Immunocytokines. (Fu, et al., 2023)

Highlight Features

Published Data

Representative data1: The study showed that an Anti-CD20-Interleukin-2 immunocytokine presents safe and active treatment efficacy in patients with relapsed and refractory B-Cell Lymphoma.

Fig.3 Promising tumor response and duration of response in 16 evaluation patients with DI-Leu16-IL2 therapy. (Lansigan, et al., 2016)

Frequently Asked Question

Q1: What are the challenges of immunocytokine engineering development?

A1: For immunocytokine engineering development, there may be various crucial challenges should be concerned:

1. to overcome the naturally rapid clearance and adverse exposure of endogenous cytokines;
2. to concentrate the cytokines delivery to diseased tissues or specific cell types to avoid systemic toxicity;
3. to develop combination regimens to achieve synergistic treatment efficacy with immune checkpoint blockade antibodies, CAR-T therapy, or gene therapy.

For more details about our Next™ Immunocytokine Engineering Development Service, please contact us with no hesitation.

References

1. Fu, Y.; et al. Engineering cytokines for cancer immunotherapy: a systematic review. Frontiers in Immunology. 2023, 14.
2. Lansigan, F.; et al. DI-Leu16-IL2, an anti-CD20-interleukin-2 immunocytokine, is safe and active in patients with relapsed and refractory B-cell lymphoma: a report of maximum tolerated dose, optimal biologic dose, and recommended phase 2 dose. Blood. 2016, 128(22):620.

For Research Use Only | Not For Clinical Use